Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Ciro Celsa; Giuseppe Cabibbo; David James PINATO

doi:10.1097/HEP.0000000000001217

Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

Ciro Celsa
, Giuseppe Cabibbo
, David James PINATO

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Recensione in rivista › peer review

Lingua originale	Inglese
Rivista	Hepatology
DOI	https://doi.org/10.1097/HEP.0000000000001217
Stato di pubblicazione	Pubblicato - 2024

Accesso al documento

10.1097/HEP.0000000000001217

https://hdl.handle.net/11579/202267

Altri file e collegamenti

handle

Cita questo

@article{aa890c7420104292b18a16648da56551,

title = "Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment",

author = "Ciro Celsa and Giuseppe Cabibbo and PINATO, \{David James\}",

year = "2024",

doi = "10.1097/HEP.0000000000001217",

language = "English",

journal = "Hepatology",

issn = "0270-9139",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment

AU - Celsa, Ciro

AU - Cabibbo, Giuseppe

AU - PINATO, David James

PY - 2024

Y1 - 2024

UR - https://iris.uniupo.it/handle/11579/202267

U2 - 10.1097/HEP.0000000000001217

DO - 10.1097/HEP.0000000000001217

M3 - Literature review

SN - 0270-9139

JO - Hepatology

JF - Hepatology

ER -